You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Neoadjuvant therapy

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neoadjuvant Immunotherapy Trial in Tianjin (tislelizumab+disitamab-vedotin)

Recruiting
  • Neoadjuvant Immunotherapy
  • Tianjin, China
    The Second Hospital of Tianjin Medical University
Apr 20, 2023

HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)

Recruiting
  • HER2-positive Breast Cancer
  • Eribulin mesylate injection、Pertuzumab、Trastuzumab
  • Guanzhou, Guangdong, China
    LI YuDong
Jul 13, 2023

TNBC - Triple-Negative Breast Cancer Trial (Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Camrelizumab Plus Chemotherapy and Famitinib
  • Camrelizumab Plus Chemotherapy
  • (no location specified)
Aug 17, 2023

Breast Tumors Trial in Guangzhou (procedure, drug, biological)

Recruiting
  • Breast Neoplasms
  • Sentinel Lymph Node Biopsy (SLNB)
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 2, 2023

Breast Cancer Undergoing Neoadjuvant Therapy

Recruiting
  • Stage I-III Breast Cancer
    • Hangzhou, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Dec 13, 2022

    Rectal Cancer Trial in Chengdu (drug, radiation, procedure)

    Recruiting
    • Rectal Cancer
    • Chengdu, Sichuan, China
      West China Hospital, Sichuan University
    Mar 8, 2023

    t Pathologic Complete Response Observed in HER2 Positive Breast

    Completed
    • HER2+ Breast Cancer
    • Rawalpindi, Punjab, Pakistan
      Rawalpindi Medical University
    Jun 26, 2023

    Breast Cancer Trial in Shanghai (axillary surgery de-escalation after NAT)

    Recruiting
    • Breast Cancer
    • axillary surgery de-escalation after NAT
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center Shanghai, China, 200032
    Jun 13, 2023

    Radiotherapy & Total Neoadjuvant Therapy for Recurrent Rectal

    Recruiting
    • Rectal Neoplasm
    • Reirradiation
    • Rome, Italy
      Fondazione Policlinico Gemelli
    Aug 2, 2023

    Resectable Pancreatic Cancer Trial in Tianjin (AG Followed by FOLFIRINOX)

    Recruiting
    • Resectable Pancreatic Cancer
    • AG Followed by FOLFIRINOX
    • Tianjin, Tianjin, China
      Rui Liu
    Jan 8, 2023

    Stage II-III Breast Cancer Trial in Shenyang (cytotoxic chemo (docetaxel or epirubicin or cyclophosphamide or carboplatin),

    Recruiting
    • Stage II-III Breast Cancer
    • cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
    • +2 more
    • Shenyang, Liaoning, China
    • +1 more
    Aug 3, 2022

    Rectal Cancer Trial in Fuzhou (radiation, drug, procedure)

    Not yet recruiting
    • Rectal Cancer
    • split-course hypofraction radiotherapy
    • +3 more
    • Fuzhou, Fujian, China
      Pan Chi
    Jul 23, 2023

    Breast Tumors Trial in Guangzhou (procedure, drug, biological)

    Recruiting
    • Breast Neoplasms
    • Sentinel Lymph Node Biopsy (SLNB)
    • +7 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Jul 31, 2023

    Rectal Cancer Trial in Hangzhou (Envafolimab)

    Recruiting
    • Rectal Cancer
    • Hangzhou, Zhejiang, China
      Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
    May 4, 2023

    Rectal Cancer Trial (CapeOX + cetuximab, CapeOX + bevacizumab, radiotherapy)

    Not yet recruiting
    • Rectal Cancer
    • CapeOX + cetuximab
    • +2 more
    • (no location specified)
    Sep 12, 2023

    Breast Cancer Trial in Nanjing (Neoadjuvant therapy: TCbHPy, Neoadjuvant therapy: TCbHP)

    Not yet recruiting
    • Breast Cancer
    • Neoadjuvant therapy: TCbHPy
    • Neoadjuvant therapy: TCbHP
    • Nanjing, China
      the First Affiliated Hospital of Nanjing Medical University
    Jul 4, 2022

    Neoadjuvent, PD-1 Inhibitor, Chemo Trial in Xi'an (Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin)

    Recruiting
    • Neoadjuvent
    • +3 more
    • Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
    • Xi'an, Shaanxi, China
    • +2 more
    Aug 17, 2023

    Prostate Cancer With =10 Bone Metastases Trial (Apalutamide, 89Sr, Luteinizing Hormone-Releasing Hormone Analog)

    Not yet recruiting
    • Prostate Cancer With ≤10 Bone Metastases
    • (no location specified)
    Feb 22, 2023

    Gastric Cancer, GastroEsophageal Cancer, Fruquintinib Trial in Nanning (Fruquintinib + SOX)

    Recruiting
    • Gastric Cancer
    • +3 more
    • Fruquintinib + SOX
    • Nanning, China
      Guangxi Medical University Cancer Hospital
    Dec 2, 2022

    Locally Advanced Rectal Cancer Trial in Beijing (Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor), Long-course

    Recruiting
    • Locally Advanced Rectal Cancer
    • Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
    • Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)
    • Beijing, Beijing, China
      Beijing Friendship Hospital, Capital Medical University
    Apr 25, 2023

    Head and Neck Squamous Cell Carcinoma, Oral Cancer Trial in Guangzhou (Tirelizumab ,+Carboplatin+albumin-bound paclitaxel)

    Recruiting
    • Head and Neck Squamous Cell Carcinoma
    • Oral Cancer
    • Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
    • Guangzhou, Guangdong, China
      Sun yat-sun memorial hospital
    Jul 10, 2023

    Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis Trial in Tianjin (Durvalumab, Surgery, Gemcitabine)

    Recruiting
    • Durvalumab
    • +2 more
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Jan 3, 2023

    Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Sep 28, 2022

    Hepatocellular Carcinoma Resectable Trial in Fuzhou (neoadjuvant therapy)

    Not yet recruiting
    • Hepatocellular Carcinoma Resectable
    • neoadjuvant therapy
    • Fuzhou, Fujian, China
      The First Affiliated Hospital of Fujian Medical University
    Aug 19, 2023

    Locally Advanced Hypopharyngeal Carcinoma Trial in Shanghai (drug, procedure, radiation)

    Not yet recruiting
    • Locally Advanced Hypopharyngeal Carcinoma
    • three cycles (toripalimab + cetuximab + platinum)
    • +2 more
    • Shanghai, Shanghai, China
      Eye & ENT Hospital of Fudan University
    Nov 22, 2023